South Asia, led by India and China, is the fastest-growing angina market due to developing economies and improved healthcare infrastructure.

NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 1, 2023 /EINPresswire.com/ -- The global prinzmetal angina therapeutics market is expected to surpass an impressive valuation of US$ 10.7 Billion in 2023 and is projected to reach US$ 17.2 Billion by 2033, trailing a CAGR of 4.85%. The development of biosimilars and biobetters, growth in diabetic and hypertension population due to unhealthy lifestyle and rise in consumption of alcohol and smoking are the significant factors responsible for fueling growth of angina market during the forecast period. Calcium-channel blocking agents are promising drugs for PVA. Verapamil hydrochloride, the prototype calcium-channel blocking agent for arrhythmias, is effective for PVA, which will drive market growth.

Nifedipine, diltiazem, and verapamil are all highly and equally effective in reducing painful and painless ischemic episodes in Prinzmetal's variant angina which will also bolster the product demand. Use of Beta-blockers, particularly propranolol and metoprolol in therapeutic use in Prinzmetal Angina will keep the market afloat. Additionally, increasing investments and spending by consumers in healthcare along with the growing prevalence and incidence of angina pectoris also heighten the overall growth of the market.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16366

However, the downward pricing pressure owing to its commodity nature restrains the market’s growth. The high cost for surgical procedures like coronary bypass surgery is also anticipated to hamper the overall growth of the market. The various technological advances in personalized cardiovascular medicine as well as the enhancement of innovative drug delivery systems are anticipated to generate lucrative opportunities for the market. On the other hand, the increased use of minimally invasive surgeries and shortage of skilled professional have the potential to challenge the market’s growth.

Key Takeaways:

North America is expected to dominate the market of Prinzmetal Angina therapeutics with a market share of 42% during the forecast period.

The product demand in South Asia is expected to move ahead with a CAGR of 4%.

China is anticipated to dominate the Prinzmetal angina drug market in South Asia

By drug class, Beta Blockers are projected to lead market with highest market share.

Hospital Pharmacies is estimated to dominate the market with a segment share of 55% during the forecast period.

US dominated the market in North America with a market share of around 40% in 2022.

One gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 anticipated to launch in the US will bolster the market during the forecast period.

“Advancements in medical therapeutics, extensive use of beta blockers and adoption of innovative drug delivery systems will bolster market growth,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Competitive Landscape:

Key players in the Prinzmetal Angina Market are:
Sanofi S.A.
Gilead Sciences; Inc.
AstraZeneca Plc
Pfizer; Inc.
Eli Lilly and Company
Amgen; Inc.
GlaxoSmithKline Plc
Tasly Pharmaceuticals; Inc.
Novartis AG,
XyloCor Therapeutics.

Some recent developments in this industry are:

In March 2022, Zydus Lifesciences received approval from the United States Food and Drug Administration (FDA) to market its Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg, and 0.6mg (US RLD: Nitrostat Sublingual Tablets) for angina.

In October 2021, BioCardia, Inc. announced the treatment of the patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with refractory angina.

Access Exclusive Insights and Unlock Special Discounts Now! Click Here for a Competitive Edge: https://www.futuremarketinsights.com/checkout/16366

More Valuable Insights:

Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug class (Beta Blockers, Calcium Antagonists, Anti-coagulants, Anti-Platelets, Anti-Anginal, ACE inhibitors, Nitrates) By disease type (Stable or chronic angina, Unstable angina, Variant and microvascular angina) By distribution channel (Online pharmacies, hospital pharmacies, retail pharmacies) and by region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Prinzmetal Angina Therapeutics Market Segmentation:

By Drug Class:

Beta Blockers
Calcium Antagonists
Anti-coagulants
Anti-Platelets
Anti-Anginal
ACE Inhibitors
Nitrates

By Disease Type:

Stable or Chronic Angina
Unstable Angina
Variant and Microvascular Angina

By Distribution Channel:

Online Pharmacies
Retail Pharmacies
Hospital Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore Future Market Insights, Inc. Extensive Coverage in Healthcare Market Domain:

Dual Balloon Angioplasty Catheter Market Trends: The global market was valued at US$ 199.8 million in 2022. In 2023, this overall market value is projected to reach US$ 204.9 million.

Cardiac Assist Devices Market Outlook: The global market is poised to surpass US$ 1.37 billion by 2023, surging at a remarkable CAGR of 6.1% through 2033 to reach US$ 2.48 billion.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.